Ibrance 125 MG tablet 7S
Ended Awarded Last action
- Contract number
- SPE2DR26FQ9XZ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,110
Award facts
- Contract value 100% obligated
- $17,110.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,110.42 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg tablets (7-count packages) under a firm fixed price contract. The award was made on November 24, 2025, with an ultimate completion date of December 16, 2025. This is an unset-aside, competitively awarded delivery order, with performance to occur at the contractor's facility in Conshohocken, Pennsylvania. Ibrance is a branded oncology medication used in cancer treatment, reflecting the critical pharmaceutical support that DLA Medical Supply Chain procures to support military and veteran healthcare systems.
This delivery order is a child contract executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, supplying a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide. The company's capacity to fulfill this oncology pharmaceutical requirement demonstrates its established capability in meeting federal healthcare procurement needs through open competition.
Quick answers
Who was awarded contract SPE2DR26FQ9XZ?
SPE2DR26FQ9XZ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 24, 2025.
How much is contract SPE2DR26FQ9XZ worth?
The government has obligated $17,110 on SPE2DR26FQ9XZ.
Is contract SPE2DR26FQ9XZ an order under another contract?
Yes. SPE2DR26FQ9XZ is a delivery order under SPE2DR25D3006, an indefinite delivery contract.
Was contract SPE2DR26FQ9XZ competed?
The extent of competition for SPE2DR26FQ9XZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award